J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

WASHINGTON--Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for ...

Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne toothpaste.

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, ...